Here are three GI companies that made headlines this week:
San Francisco-based Versant Ventures launched Jecure Therapeutics on Feb. 15, 2017. Jecure is a biotech company with a proprietary liver disease platform. To date, it has developed treatment programs for non-alcoholic steatohepatitis and fibrosis.
Japan-based Takeda acquired Cambridge, Mass.-based Ariad Pharmaceuticals for $24 per share. New York City-based law firm Faruqi & Faruqi previously investigated whether Ariad properly executed fair sale practices.
Laval, Canada-based Valeant’s move to sell $2.1 billion in assets in January 2017 positively impacted its debt pathway. Valeant can cover its August 2018 bond when it matures.
More articles on gastroenterology:
GI leader to know: Dr. Shahab Aftahi of Estrella Gastroenterology
Versant Ventures launches Jecure Therapeutics: 4 key notes
Study associates Barrett’s esophagus with early-stage GI cancers: 3 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
